Attached files
file | filename |
---|---|
EX-31.2 - EX-31.2 - TETRAPHASE PHARMACEUTICALS INC | d847135dex312.htm |
EX-31.1 - EX-31.1 - TETRAPHASE PHARMACEUTICALS INC | d847135dex311.htm |
EX-21.1 - EX-21.1 - TETRAPHASE PHARMACEUTICALS INC | d847135dex211.htm |
EX-23.1 - EX-23.1 - TETRAPHASE PHARMACEUTICALS INC | d847135dex231.htm |
EX-32.1 - EX-32.1 - TETRAPHASE PHARMACEUTICALS INC | d847135dex321.htm |
EX-10.27 - EX-10.27 - TETRAPHASE PHARMACEUTICALS INC | d847135dex1027.htm |
EX-10.26 - EX-10.26 - TETRAPHASE PHARMACEUTICALS INC | d847135dex1026.htm |
EXCEL - IDEA: XBRL DOCUMENT - TETRAPHASE PHARMACEUTICALS INC | Financial_Report.xls |
10-K - FORM 10-K - TETRAPHASE PHARMACEUTICALS INC | d847135d10k.htm |
EXHIBIT 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Tetraphase Pharmaceuticals, Inc. (the Company) for the fiscal year ended December 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the Report), the undersigned, David Lubner, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that, to his knowledge on the date hereof:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 6, 2015
/s/ David C. Lubner |
David C. Lubner Senior Vice President and Chief Financial Officer |